Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: Results of the EORTC 18961 randomized phase III trial

Journal of Clinical Oncology

Volumn 31, Issue 30, 2013, Pages 3831-3837

  Eggermont, Alexander M M ^a,p,q   Suciu, Stefan ^b   Rutkowski, Piotr ^c   Marsden, Jeremy ^d   Santinami, Mario ^h   Corrie, Philippa ^e   Aamdal, Steinar ^l   Ascierto, Paolo A ⁱ   Patel, Poulam M ^f   Kruit, Wim H ^m   Bastholt, Lars ⁿ   Borgognoni, Lorenzo ^j   Bernengo, Maria Grazia ^k   Davidson, Neville ^g   Polders, Larissa ^b   Praet, Michel ^b   Spatz, Alan ^o  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b EORTC DATA CENTER   (Belgium)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g BROOMFIELD HOSPITAL   (United Kingdom)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^k University Hospital of Turin   (Italy)

^l OSLO UNIVERSITY HOSPITAL   (Norway)

^m ERASMUS MEDICAL CENTER   (Netherlands)

ⁿ ODENSE UNIVERSITY HOSPITAL   (Denmark)

^o MCGILL UNIVERSITY   (Canada)

^p UNIVERSITÉ PARIS SACLAY   (France)

^q Cancer Institute Gustave Roussy   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GM2; KEYHOLE LIMPET HEMOCYANIN; QS 21; CANCER VACCINE; HEMOCYANIN; IMMUNOLOGICAL ADJUVANT; KEYHOLE-LIMPET HEMOCYANIN; SAPONIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL OBSERVATION; CLINICAL OUTCOME; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SKIN TUMOR; VERY ELDERLY; WATCHFUL WAITING; CLINICAL TRIAL; SKIN NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; DISEASE-FREE SURVIVAL; FEMALE; G(M2) GANGLIOSIDE; HEMOCYANIN; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SAPONINS; SKIN NEOPLASMS; WATCHFUL WAITING;

EID: 84891696055     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.9303     Document Type: Article

References (22)

1. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206, 2009
2. Hamilton WB, Helling F, Lloyd KO, et al: Ganglioside expression on human malignant melanoma assessed by quantitative immune thin layer chromatography. Int J Cancer 53:566-573, 1993
3. Lloyd KO, Gordon CM, Thampoe IJ, et al: Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cell. Cancer Res 52:4948-4953, 1992
4. Tsuchida T, Saxton RE, Morton DL, et al: Gangliosides of human melanoma. J Natl Cancer Inst 78:45-53, 1987
5. Jones PC, Sze LL, Liu PY, et al: Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 66:249-254, 1981
6. Livingston PO, Natoli EJ, Calves MJ, et al: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci U S A 84:2911-2915, 1987
7. Swerdlow RD, Ratliff TL, La Regina M, et al: Immunotherapy with keyhole limpet hemocyanin: Efficacy and safety in the MB-49 intravesical murine bladder tumor model. J Urol 151:1718-1722, 1994
8. Livingston PO, Adluri S, Helling F, et al: Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma. Vaccine 12:1275-1280, 1994
9. Livingston PO, Wong GY, Adluri S, et al: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994
10. Investigator brochure: GM2-KHL/QS-21 vaccine. Tarrytown, NY, Progenics Pharmaceuticals, 2001
11. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
12. Freedman LS, White SJ: On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 32:691-694, 1976
13. Fleming TR, Harrington DP, O'Brien PC: Designs for group sequential tests. Control Clin Trials 5:348-361, 1984
14. Kalbfleisch JD, Prentice RL: The Survival Analysis of Failure Time Data (ed 2). Hoboken, NJ, Wiley Inter-Science, 2002
15. Eggermont AM, Suciu S, Ruka W, et al: EORTC18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4 N0M0) melanoma-2nd interim analysis led to an early disclosure of the results. J Clin Oncol 26:484s, 2008 (suppl; abstr 9004)
16. Eggermont AM: Therapeutic vaccines in solid tumours: Can they be harmful? Eur J Cancer 45: 2087-2090, 2009
17. Morton DL, Mozzillo N, Thompson JF, et al : An international, randomized, phase 3 trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 25:474s, 2007 (suppl; abstr 8508)
18. Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001
19. Wheatley K, Ives N, Hancock B, et al: Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29:241-252, 2003
20. Mocellin S, Pasquali S, Rossi CR, Nitti D: Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and metaanalysis. J Natl Cancer Inst 102:493-501, 2010
21. Eggermont AM, Testori A, Maio M, et al: Anti-CTLA-4 antibody adjuvant therapy in melanoma. Semin Oncol 37:455-459, 2010
22. Sarnaik AA, Yu B, Yu D, et al: Extended dose ipilimumab with a peptide vaccine: Immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 17:896-906, 2011